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Tall cell variant (TCV) of papillary thyroid carcinoma (PTC), an aggressive form of thyroid cancer, is characterised by 50% of cells
with height that is three times greater than the width. Very rarely, some of these cancers can progress to spindle cell squamous
carcinoma (SCSC) resulting in cancers with elements of both SCSC and TCV PTC. Here we report a case of SCSC arising from
TCV PTC. In addition to this case, we have performed a literature review and compiled all published reports of SCSC arising from
TCV PTC, including the nature of treatment and the prognosis for each of the 20 patients recorded. This is intended for use as a
guide for clinicians in what the most appropriate treatment options may be for a newly diagnosed patient. Due to the rarity coupled
with diagnosis occurring at a very advanced stage of disease progression, performing clinical trials is difficult and therefore drawing
conclusions on optimal treatment methods remains a challenge.
1. Introduction
First described by Hawk and Hazard in 1976, tall cell variant
(TCV) of papillary thyroid carcinoma (PTC) is defined as an
aggressive thyroid tumour, with 50 per cent of cells having
height at least two or three times greater than width and
bearing nuclear characteristics of PTC [1, 2]. Interestingly,
some cases of TCV PTC progress to spindle cell squamous
carcinoma (SCSC) which is a rare form of anaplastic carci-
noma, consisting of both spindle cell elements and squamous
islands with focal keratinization [3, 4]. TCV PTC associated
with SCSC can be divided into three types as described by
Gopal et al. [5]. We present a rare case of type 1 anaplastic
SCSC arising from TCV PTC, highlighting the diagnostic
challenges, as well as a review of the literature of all reported
type 1 cases.
2. Case
In April 2011, a 51-year-old man presented to his primary
care physician with symptoms of a mild sore throat and
haemoptysis. Antibiotics were commenced for a presumed
bacterial infection. He presented again two months later
with shortness of breath and stridor and was referred to
an Otolaryngologist for further care. Clinically, the patient
was euthyroid and examination of the neck revealed a right-
sided thyroid swelling with no lymphadenopathy. Blood tests
were performed, including full blood count, thyroid function,
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Figure 1: Neck CT scan showing the invasion of the trachea.
Figure 2: T1 MRI of neck showing invasion of trachea.
calcium, phosphate, and vitamin D levels, and were all
normal. The patient subsequently underwent an ultrasound
scan (USS) and fine needle aspiration of the thyroid gland
and was prescribed a short course of oral prednisolone.
The results of the fine needle aspiration cytology (FNAC)
suggested papillary carcinoma of the thyroid. Following
steroid treatment, the patient was experiencing worsening
haemoptysis, shortness of breath, and stridor associated with
dizziness. The initial computer tomography (CT) scan of his
neck revealed a mass extending from the posterior aspect
of the right thyroid lobe, and further CT and magnetic
resonance imaging (MRI) scan of the neck demonstrated
that the thyroid mass had eroded into the trachea (Figures 1
and 2). Oral dexamethasone was commenced and the patient
was referred to Hammersmith Hospital. A tracheoscopy was
performed and vertical intraluminal tumour involvement
was measured at 5 cm (Figure 3). The patient had no known
drug allergies and his past medical history included hyperc-
holesterolaemia which was controlled with medication.
The patient underwent a total thyroidectomy in Septem-
ber 2011, manubrial split (with levels 6 and 7 node dissection),
and tracheal resection. End-to-end tracheal anastomosis was
achieved with insertion of a tracheal stent and formation
of a tracheostomy. The right recurrent laryngeal nerve was
sacrificed owing to extensive tumour infiltration. Intraop-
eratively, the resected trachea was sent for frozen section
histological analysis.The superior and inferiormargins of the
tracheal resection were clear of tumour and the specimenwas
Figure 3: Tracheoscopy showing invasion of trachea from thyroid
tumour.
reported as a moderately to poorly differentiated squamous
cell carcinoma of the thyroid invading and ulcerating the
tracheal mucosa.
Although the patient was found to be hypocalcaemic
postoperatively, he made an uncomplicated recovery and
the tracheostomy was removed 14 days following surgery.
He was discharged with calcium supplementation. The case
was discussed at the Thyroid Cancer Multidisciplinary Team
Meeting where a decision was made to offer the patient a
course of chemoradiotherapy.
Unfortunately, the patient died 4weeks following hospital
discharge.
3. Materials and Methods
The literature review was performed using the PubMed
database from 1961 to 2012. The terms “thyroid” and “thyroid
gland” were used in conjunction with “tall cell variant
papillary carcinoma” and/or “squamous cell carcinoma” or
“spindle cell squamous cell carcinoma.” A total of 162 articles
were generated from the search of which only articles with
cases documenting SCSC arising from TCV were included.
Of the 162 articles, 3 were identified and a total number of
19 cases of documented SCSC arising from TCV PTC were
included (Supplementary Table 1 in Supplementary Material
available online at https://doi.org/10.1155/2017/4581626).
4. Histology
The thyroid contained a 5 cm tumour which showed two
distinct morphologies. Part of the tumour (which was pre-
dominantly centred in the thyroid) showed features of pap-
illary carcinoma including papillary architecture (with tall,
well-formed papillae) and tumour cells that were columnar
in shape, with nuclei showing overlapping, clearing, and
pseudoinclusions (Figure 4(a)). As the length of the tumour
cells was more than twice the width, the appearances were
interpreted as those of the tall cell variant (of papillary
carcinoma).
In addition, approximately 60–70%of the tumour showed
features of moderately to poorly differentiated squamous cell
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Figure 4: Histology of the tumour. (a) Features of papillary carcinoma including papillary architecture (with tall, well-formed papillae)
and tumour cells that were columnar in shape, with nuclei showing overlapping, clearing, and pseudoinclusions. (b) Moderately to poorly
differentiated squamous cell carcinoma. (c) Moderately to poorly differentiated squamous cell carcinoma with spindle cell elements. (d)
Positive for (nuclear) thyroid transcription factor-1 (TTF-1) and Galectin-3 (cytoplasmic) in both components.
carcinoma (Figure 4(b)) with spindle cell elements (Fig-
ure 4(c)).
The two components were intimately admixed and there
were areas of transition from the papillary component to the
squamous component.
Immunohistochemical analysis showed positivity for
(nuclear) thyroid transcription factor-1 (TTF-1) and Galec-
tin-3 (cytoplasmic) in both components (Figure 4(d)). Thy-
roglobulin was expressed in the papillary component, but
not the squamous/spindle cell component. P63 was positive
in the squamous component. The Ki67 proliferation index
varied between 5% in the papillary component and 40% in
the squamous component.
Extensive extrathyroidal extension was noted with inva-
sion of the trachea and skeletal muscle. There was also
widespread lymphovascular invasion and metastatic tumour
was present in three lymph nodes.
5. Discussion
Thyroid carcinoma, being the most common endocrine
malignancy, has an overall estimated incidence of 7.7 per
100,000.
TCV PTC is an aggressive tumour characterised by its
tall columnar shape, with a height : width ratio of 2-3 : 1
and abundant eosinophilic or oxyphilic cytoplasm [1, 2,
6, 7]. Although a rare occurrence, TCV PTC may trans-
form into anaplastic SCSC. TCV PTC is associated with
adverse prognostic features including large tumour size,
extrathyroidal extension, and vascular invasion, with a high
incidence of locoregional recurrence, distant metastasis, and
shorter disease-free survival [6, 8–14]. In addition, TCV
possesses a more aggressive phenotype than conventional
PTC, independent of age, gender, and tumour size [15]. On
close examination of the cell cycle regulatory proteins such
as p27, Ki67 cyclin D1, and P53 and eukaryotic translation
initiation factors 4E and 2 alpha expression, TCV exhibits
a molecular profile which is comparable to thyroid tumours
with an unfavourable prognosis [4, 16–19].
Three main types of anaplastic SCSC arising from TCV
PTChave been described byGopal et al. based on histological
examination: type 1 is defined by the presence of both TCV
and SCSC within the initial resection; type 2 occurs when
the SCSC component arises as a recurrence or metastasis
in patients with a known history of TCV; type 3 is defined
as SCSC presenting as a primary laryngeal squamous cell
carcinoma in patients with or without a known history of
TCV [5].
This case presented some diagnostic difficulties. Ultra-
sound guided FNAC is a useful tool in the investigation
workup of thyromegaly but has proven to be misleading
in many studies [20–22]. The initial FNAC result, in this
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Table 1: The table shows demographics, clinicopathologic features,
treatment, outcome, and follow-up of patients with anaplastic SCSC
arising from TCV PTC. (Data based on the 20 reported cases
including present case.)
Patient demographics & clinicopathologic features
Number of patients 20
Median age (years) 71
Male : female ratio 1 : 1.5
Thyroid swelling 80% (16/20)
Thyroid nodule(s) 20% (4/20)
Thyroid profile
Euthyroid 5% (1/20)
Not reported 95% (19/20)
Treatment
Surgery 5% (1/20)
Surgery + chemotherapy/radiotherapy 5% (1/20)
Not reported 90% (18/20)
Outcome & follow-up
Alive 5% (1/20)
Death from tumour 5% (1/20)
Disease-free follow-up 6 months
Follow-up not reported 90% (18/20)
case, suggested PTC, which was misleading. When assessing
the time course and severity of the patient’s progressive
symptoms coupled with the results of the CT andMRI scans,
a working diagnosis of PTC becomes less likely. Secondly,
the tracheal resection sent frozen section histological analysis
revealed a diagnosis of moderately to poorly differentiated
squamous cell carcinoma (SCC). This scenario implied that
there was a greater possibility that the patient possessed two
primary tumours (PTC and laryngeal SCC) as opposed to
both tumour components arising from the thyroid gland.
The patient presented in this case was eventually defined
as having the type 1 variant of anaplastic SCSC arising from
TCVPTCowing to the histological assessment of the resected
specimen which revealed both SCSC and TCV. Although
TTF-1 reactivity has also been shown to be present in primary
squamous tumours of the lung [23, 24], its positivity along
with Galectin-3 within the SCSC component implies that the
latter originated from the thyroid gland.
On careful review on the current literature documenting
anaplastic SCSC arising from TCV PTC, only the case series
presented by Gopal et al. [5] (14 cases), Saunders and Nayar
[25] (1 case), and Johnson et al. [6] (4 cases) have cases that
demonstrate type 1 variant of this rare disease. Although
Gopal et al. present 18 cases of type 1 anaplastic SCSC arising
from TCV PTC only 14 of these are documented to have an
SCSC component along with the TCV component of tumour
[5]. Of the 5 cases presented by Bronner and LiVolsi, only 4
fall within the type 1 scenario [3] (Supplementary Table 1).
The median age at presentation is 71 years with females
being more affected than males (1.5 : 1, resp.) (Table 1). Of
the 20 cases reviewed, 16 (80%) presented with a rapidly
enlarging thyroid mass whereas 4 (20%) presented with a
thyroid nodule. Thyroid profile status was difficult to ascer-
tain owing to a lack of reporting. With regard to treatment,
the patient in this case underwent a total thyroidectomy
and another patient underwent completion thyroidectomy
and adjuvant chemoradiotherapy; 90% (18/20) of cases did
not have documented treatment regimes. Regarding outcome
and follow-up, 1 patient of 20 was reported to be alive
after 6 months and the patient in this case deceased 4
weeks following surgery; 18 of 20 cases (90%) did not have
documented prognosis and follow-up. The lack of outcome
reporting is due to the rarity as well as aggressiveness (with
survival rates of 20% at one year) of this unusual type of
thyroid tumour and therefore makes development of an
optimal treatment strategy a definite challenge [26].
The difficulties highlighted by this case are, firstly, the
diagnosis of type 1 SCSC arising from TCV PTV. This is
essentially a histological diagnosis, and as shown in this case,
the FNAC results can be unreliable. Secondly, the rarity of this
type of thyroid carcinoma coupled with late presentation has
not allowed for a treatment regime to be established. When
considering other types of aggressive thyroid tumours (e.g.,
anaplastic thyroid carcinoma) and their treatment, it is pos-
sible to suggest the use of chemoradiation coupled following
surgical resection [27]. Another problem in the identification
of new treatments for the type of thyroid carcinoma reported
in this case is the rarity and aggressiveness of the tumour,
rendering difficulty in recruiting patients who are clinically
suited to participate in clinical trials.
6. Conclusion
We present the 20th documented case of type 1 anaplastic
SCSC arising from TCV PTC highlighting the challenges
in the diagnostic workup and a thorough review of all
cases in the medical literature. This extremely rare neoplastic
phenomenon forms a very small percentage of thyroid
carcinomas and with its rarity and highly advanced stage
of disease progression at presentation, recruiting patients
to participate in clinical trials will inevitably lead to poor
response rates from conventional and even newly emerging
treatment regimens.
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